The Man Who Bench-Presses 100kg — and What That Has to Do With Drug Discovery

On the 13th of February 2026, Denis Milov walked out of a Moscow hospital — not for the first time. Four days of tests, an MRI, the usual neurology ward routine. The verdict: remission. No new lesions. No disease progression since the previous scan.

For most patients, this would be unremarkable. For Denis, it was the latest data point in an experiment that has been running for sixteen years — with his own body as the subject.

The first sign was an eye twitch. Barely noticeable at first. Then it became a full facial spasm — every fifteen seconds, around the clock. He would fall asleep only from sheer exhaustion. Then came the coordination problems. He stopped being able to walk without support. He lost fourteen kilograms. On windy days, gusts knocked him to the ground.

Every few months, he quietly looked for freelance work — anything to ease the financial weight on his family, to feel less like a burden to the wife and children who were watching him disappear.

“I thought I was going to die.”

— Denis Milov

Interferon, the standard treatment he had been prescribed, kept the acute relapses at bay. But it could not stop what was happening underneath: the slow, relentless erosion of neurological function that defines the progressive face of this disease. This is the problem that has haunted MS medicine for decades. We learned to fight the fire. We never learned to rebuild what burned.

There are approximately three million people living with multiple sclerosis worldwide. One is diagnosed every five minutes. The disease most commonly strikes between 30 and 59 — the years when people are building careers, raising families, running companies.

The last decade brought genuine advances. Anti-CD20 biologics changed the prognosis for primary progressive MS. A new class of oral therapies — BTK inhibitors — is now in late-stage trials, and the first provisional approval in the UAE was granted in July 2025. These drugs reach compartmentalised inflammation deep inside the central nervous system, further than any previous treatment could.

But even the best of them leave one question unanswered. Leading clinical research organisations note in their latest analyses that disability progression often occurs independently of relapse activity. Stopping the inflammation does not restore what was already lost.

The next frontier is not suppression. It is regeneration.

There is something else that rarely gets said plainly. Multiple sclerosis is not considered a hereditary disease — but that is not entirely accurate. Research in several countries shows a meaningful genetic predisposition, with children of MS patients facing substantially higher risk. Early screening — before symptoms appear, before a first MRI reveals what should have been caught earlier — changes the equation entirely. For a young person with a predisposition, timely intervention means the difference between a life that unfolds and a life that must be fought for, centimetre by centimetre, for decades.

Denis arrived at this conclusion not through a literature review, but through his own recovery.

He began training — obsessively, systematically. Large muscle groups, every day, building mass against the illness that was steadily trying to reclaim it. And slowly, something happened that no doctor had predicted: neurological function began to improve. Not in a way that any single scan could capture as a miracle. But measurably, over years.

Today, Denis bench-presses 100 kilograms. His most recent MRI shows no new lesions — a picture that has been stable across multiple scans since 2020. His EDSS score, the standard clinical measure of MS-related disability, is 4.0: he walks more than a kilometre without assistance. For someone who once could not walk at all, and who has lived with active MS for sixteen years, this is not nothing.

The biology behind it points toward a precise mechanism. Intensive resistance training is one of the most reliable stimulants of IGF-1 — insulin-like growth factor 1. IGF-1, in turn, has documented neuroprotective properties: it promotes neuronal survival and supports the repair of myelin, the insulating sheath that MS progressively destroys. Denis did not design a clinical trial. He risked himself to find out the answer: was it possible to lift his head? To sit up in the hospital bed? To stand, and take the first steps? To come back to life.

Denis and his team launched a biotech research venture in the United Arab Emirates — VOSTOK ONE, incorporated at Masdar City, Abu Dhabi — which is now running the science.

The MS programme is part of a broader portfolio brought together by the scientists who gave Denis a second chance. 30+ patent families across 19 jurisdictions, developed under the scientific direction of a molecular biologist with twenty years of research in gene and cell therapy from St Petersburg.

The question the programme is designed to answer is precise: can IGF-1-based intervention systematically stimulate the neurological repair that Denis experienced individually? Can it be made into a reproducible, scalable medicine — safe and effective enough for regulatory approval? That is the work. It proceeds at the pace that serious drug development requires: methodical, evidence-bound, and grounded in biology that was tested on a human being before it was ever written into a research protocol.

The goal is not to help people cope. It is to bring them back — to work, to family, to movement, to the life that MS takes away so gradually that some people barely notice what they’ve lost until it’s gone. Denis walked this path alone, for sixteen years, through stubbornness and a barbell and a piece of biology he understood before science had named it. The technology VOSTOK ONE is developing is designed to make that path available to those who don’t have his willpower, his time — or his luck.

Multiple sclerosis is diagnosed every five minutes. Three million people are waiting for something that does more than slow the damage.

Denis Milov is one of them. He is also, now, one of the people working on the answer.